Functional Classification of BRCA2 DNA Variants by Splicing Assays in a Large Minigene with 9 Exons

ABSTRACT Numerous pathogenic DNA variants impair the splicing mechanism in human genetic diseases. Minigenes are optimal approaches to test variants under the splicing viewpoint without the need of patient samples. We aimed to design a robust minigene construct of the breast cancer gene BRCA2 in order to investigate the impact of variants on splicing. BRCA2 exons 19–27 (MGBR2_ex19–27) were cloned in the new vector pSAD. It produced a large transcript of the expected size (2,174 nucleotides) and exon structure (V1‐ex19‐27‐V2). Splicing assays showed that 18 (17 splice‐site and 1 silencer variants) out of 40 candidate DNA variants induced aberrant patterns. Twenty‐four anomalous transcripts were accurately detected by fluorescent‐RT‐PCR that were generated by exon‐skipping, alternative site usage, and intron‐retention events. Fourteen variants induced major anomalies and were predicted to disrupt protein function so they could be classified as pathogenic. Furthermore, minigene mimicked previously reported patient RNA outcomes of seven variants supporting the reproducibility of minigene assays. Therefore, a relevant fraction of variants are involved in breast cancer through splicing alterations. MGBR2_ex19–27 is the largest reported BRCA2 minigene and constitutes a valuable tool for the functional and clinical classification of sequence variations. A large fraction of DNA variants alter the splicing process in human genetic diseases. Hybrid minigenes are valuable tools to classify variants under the splicing perspective without the need of patient RNA. In this article we describe the largest reported minigene of the breast cancer gene BRCA2 with 9 exons and the splicing functional assays of 40 candidate variants.